Over the past 16 months, Chinese-domiciled biopharmaceutical companies have emerged as significant players in the global drug development landscape, participating…
Read More

Over the past 16 months, Chinese-domiciled biopharmaceutical companies have emerged as significant players in the global drug development landscape, participating…
Read More
The U.S. Food and Drug Administration (FDA) has recently issued a significant approval for AbbVie’s antibody-drug conjugate (ADC) targeting blastic…
Read More
The pharmaceutical industry, a bedrock of global health and economic advancement, is increasingly defined by its borderless nature. Today’s drug…
Read More
The landscape of mental healthcare is on the cusp of a significant transformation with the burgeoning approval of psychedelic-assisted therapies.…
Read More
The healthcare industry, a cornerstone of global well-being, paradoxically contributes an estimated 4.4% of total global emissions annually, placing it…
Read More
Sanofi has secured a significant milestone in its development of venglustat, an innovative oral glucosylceramide synthase inhibitor (GCSi), with the…
Read More
In a significant move poised to accelerate the development of novel cancer treatments, global pharmaceutical giant Pfizer and leading Chinese…
Read More
The burgeoning field of radiopharmaceutical therapies, once confined to niche applications, is rapidly ascending to become a mainstream pillar of…
Read More
In a significant development for respiratory healthcare in the United Kingdom, the National Institute for Health and Care Excellence (NICE)…
Read More
The explosive growth of global obesity trials, fueled by the success of GLP-1 receptor agonist therapies, presents a critical challenge:…
Read More